TrialPituitary2026

Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial.

David R Clemmons et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.